Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 1
2006 1
2013 1
2014 1
2015 5
2016 1
2017 2
2018 10
2019 6
2020 9
2021 4
2022 9
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Copy Number Variation in Inflammatory Breast Cancer.
Hazra A, O'Hara A, Polyak K, Nakhlis F, Harrison BT, Giordano A, Overmoyer B, Lynce F. Hazra A, et al. Among authors: nakhlis f. Cells. 2023 Apr 4;12(7):1086. doi: 10.3390/cells12071086. Cells. 2023. PMID: 37048158 Free PMC article.
Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial.
Weiss A, Li T, Desai NV, Tung NM, Poorvu PD, Partridge AH, Nakhlis F, Dominici L, Sinclair N, Spring LM, Faggen M, Constantine M, Krop IE, DeMeo M, Wrabel E, Alberti J, Chikarmane S, Tayob N, King TA, Tolaney SM, Winer EP, Mittendorf EA, Waks AG. Weiss A, et al. Among authors: nakhlis f. J Am Coll Surg. 2023 Aug 1;237(2):247-256. doi: 10.1097/XCS.0000000000000761. Epub 2023 May 17. J Am Coll Surg. 2023. PMID: 37194964 Clinical Trial.
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Lynce F, Stevens LE, Li Z, Brock JE, Gulvady A, Huang Y, Nakhlis F, Patel A, Force JM, Haddad TC, Ueno N, Stearns V, Wolff AC, Clark AS, Bellon JR, Richardson ET, Balko JM, Krop IE, Winer EP, Lange P, Hwang ES, King TA, Tolaney SM, Thompson A, Gupta GP, Mittendorf EA, Regan MM, Overmoyer B, Polyak K. Lynce F, et al. Among authors: nakhlis f. Breast Cancer Res. 2024 Jan 31;26(1):20. doi: 10.1186/s13058-024-01774-0. Breast Cancer Res. 2024. PMID: 38297352 Free PMC article. Clinical Trial.
Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer.
Garrido-Castro AC, Regan MM, Niman SM, Nakhlis F, Remolano C, Rosenbluth JM, Block C, Warren LE, Bellon JR, Yeh E, Harrison BT, Troll E, Lin NU, Tolaney SM, Overmoyer B, Lynce F. Garrido-Castro AC, et al. Among authors: nakhlis f. NPJ Breast Cancer. 2023 Jun 2;9(1):50. doi: 10.1038/s41523-023-00555-w. NPJ Breast Cancer. 2023. PMID: 37268625 Free PMC article.
Ductal carcinoma in situ.
Nakhlis F, Morrow M. Nakhlis F, et al. Surg Clin North Am. 2003 Aug;83(4):821-39. doi: 10.1016/S0039-6109(03)00072-0. Surg Clin North Am. 2003. PMID: 12875598 Review.
HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications.
Tarantino P, Niman SM, Erick TK, Priedigkeit N, Harrison BT, Giordano A, Nakhlis F, Bellon JR, Parker T, Strauss S, Jin Q, King TA, Overmoyer BA, Curigliano G, Regan MM, Tolaney SM, Lynce F. Tarantino P, et al. Among authors: nakhlis f. Eur J Cancer. 2022 Oct;174:277-286. doi: 10.1016/j.ejca.2022.07.001. Eur J Cancer. 2022. PMID: 36116830
Molecular determinants of post-mastectomy breast cancer recurrence.
Keene KS, King T, Hwang ES, Peng B, McGuire KP, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic AK, Hudis C, Wolff AC, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam F. Keene KS, et al. Among authors: nakhlis f. NPJ Breast Cancer. 2018 Oct 12;4:34. doi: 10.1038/s41523-018-0089-z. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 30345349 Free PMC article.
49 results